Puretech Health Plc Stock Fundamentals
| PTCHFDelisted Stock | USD 3.13 0.00 0.00% |
PureTech Health plc fundamentals help investors to digest information that contributes to PureTech Health's financial success or failures. It also enables traders to predict the movement of PureTech Pink Sheet. The fundamental analysis module provides a way to measure PureTech Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PureTech Health pink sheet.
PureTech |
PureTech Health plc Company Return On Equity Analysis
PureTech Health's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current PureTech Health Return On Equity | -0.0152 |
Most of PureTech Health's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PureTech Health plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, PureTech Health plc has a Return On Equity of -0.0152. This is 99.94% lower than that of the Healthcare sector and 99.96% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 95.1% lower than that of the firm.
PureTech Health plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PureTech Health's current stock value. Our valuation model uses many indicators to compare PureTech Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PureTech Health competition to find correlations between indicators driving PureTech Health's intrinsic value. More Info.PureTech Health plc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PureTech Health's earnings, one of the primary drivers of an investment's value.PureTech Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PureTech Health's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PureTech Health could also be used in its relative valuation, which is a method of valuing PureTech Health by comparing valuation metrics of similar companies.PureTech Health is currently under evaluation in return on equity category among its peers.
PureTech Fundamentals
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (9.87) % | ||||
| Current Valuation | 654.5 M | ||||
| Shares Outstanding | 278.81 M | ||||
| Shares Owned By Insiders | 15.48 % | ||||
| Shares Owned By Institutions | 72.20 % | ||||
| Price To Earning | 158.00 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 51.23 X | ||||
| Revenue | 9.98 M | ||||
| Gross Profit | 17.39 M | ||||
| EBITDA | (46.95 M) | ||||
| Net Income | (60.56 M) | ||||
| Cash And Equivalents | 368.03 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 14.26 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (158.27 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 95 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 901.7 M | ||||
| Total Asset | 946.01 M | ||||
| Z Score | 37.8 | ||||
| Net Asset | 946.01 M |
About PureTech Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PureTech Health plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PureTech Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PureTech Health plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PURETECH HEALTH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 95 people.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in PureTech Pink Sheet
If you are still planning to invest in PureTech Health plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PureTech Health's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |